Group 1 - Prime Medicine, Inc. closed its underwritten public offering of 43,700,000 shares of common stock at a price of $3.30 per share, raising approximately $144.2 million in gross proceeds before expenses [1] - The offering included the full exercise of the underwriters' option to purchase an additional 5,700,000 shares, with no discounts or commissions for 1,818,181 shares sold to the Cystic Fibrosis Foundation [1] - TD Cowen and BMO Capital Markets served as joint book-running managers for the offering [2] Group 2 - The shares were offered under an effective shelf registration statement filed with the SEC on November 3, 2023, and declared effective on November 13, 2023 [3] - A final prospectus supplement detailing the terms of the offering was filed with the SEC and is available on their website [3] Group 3 - Prime Medicine is focused on developing a new class of one-time curative genetic therapies using its proprietary Prime Editing platform, which aims for precise and efficient gene editing [6] - The company is advancing a diversified portfolio of investigational therapeutic programs in core areas such as liver, lung, immunology, and oncology, targeting diseases with well-understood biology [7]

Core Points - Prime Medicine, Inc. announced a public offering of 38,000,000 shares at a price of $3.30 per share, aiming to raise approximately $125.4 million in gross proceeds before expenses [1] - The offering includes a 30-day option for underwriters to purchase an additional 5,700,000 shares [1] - The offering is expected to close around August 1, 2025, pending customary closing conditions [1] Company Overview - Prime Medicine is a biotechnology company focused on developing one-time curative genetic therapies using its proprietary Prime Editing platform, which allows for precise gene editing [6] - The company is advancing a portfolio of investigational therapeutic programs in core areas such as liver, lung, immunology, and oncology, targeting diseases with well-understood biology [7] Offering Details - The shares are being offered under an effective shelf registration statement filed with the SEC on November 3, 2023, and declared effective on November 13, 2023 [3] - The final prospectus supplement will be filed with the SEC and will be available through designated contacts [4]

Core Points - Prime Drink Group Corp. has extended the expiry date of its rights offering to August 29, 2025, while all other terms remain unchanged [1][2] - The rights offering includes a maximum of 353,409,888 rights, allowing shareholders to subscribe for shares at a price of $0.0825 each [2] - The company has experienced a delay in filing its audited annual financial statements for the year ended March 31, 2025, due to a change in auditors [4][5] - A management cease trade order has been imposed on the CEO and CFO until the annual financial filings are submitted [6] - The company plans to issue default status reports every two weeks until the annual financial filings are completed [7] - Prime Drink Group is focused on becoming a leading diversified holding company in the beverage, influencer media, and hospitality sectors [8]

CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of shares of its common stock. Prime Medicine also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of its common stock offered in the public offering. All of the shares ...

Group 1 - Prime Medicine, Inc. (PRME) has reached an important support level and recently experienced a "golden cross" event, indicating a potential bullish breakout [1][4] - A golden cross occurs when a security's short-term moving average (50-day) crosses above its long-term moving average (200-day), suggesting stronger breakouts [2] - The golden cross pattern consists of three stages: a downtrend followed by a crossover and then an upward price movement [3] Group 2 - PRME has rallied 40.3% over the past four weeks and currently holds a 2 (Buy) rating on the Zacks Rank, indicating potential for further gains [4] - The positive earnings outlook for PRME is supported by no earnings estimate cuts and one revision higher in the past 60 days, with the Zacks Consensus Estimate also increasing [4][5] - The combination of earnings estimate revisions and technical indicators suggests that investors should monitor PRME for potential gains in the near future [5]

Core Insights - Prime Medicine has secured up to $24 million in additional funding from the Cystic Fibrosis Foundation to accelerate the development of Prime Editors for cystic fibrosis (CF) [1][2][3] - The funding aims to enhance Prime Editing technology, which has the potential to correct a wide range of genetic mutations affecting over 93% of individuals with CF [1][2] - The initial focus will be on the G542X mutation, a prevalent CF-causing mutation with no current therapies available [2] Company Overview - Prime Medicine is a biotechnology company dedicated to developing one-time curative genetic therapies using its proprietary Prime Editing platform, which allows precise and efficient gene editing [5][6] - The company is advancing a diversified portfolio of therapeutic programs targeting liver, lung, immunology, and oncology diseases [6][7] - Prime Editing technology is designed to minimize unwanted DNA modifications while effectively repairing various genetic mutations across different tissues and organs [5] Funding Details - The CF Foundation's investment builds on an earlier agreement from January 2024 and will be provided in two tranches, with the first tranche including a $6 million equity investment [2][3] - The funding is contingent upon meeting certain scientific milestones and closing conditions [3] Disease Context - Cystic fibrosis is a serious genetic disease caused by mutations in the CFTR gene, affecting approximately 100,000 people globally, including over 40,000 in the United States [4] - Current disease-modifying therapies are not curative and may be ineffective for certain mutations, highlighting the need for innovative treatments [4]

Core Insights - Prime Medicine, Inc. (NASDAQ: PRME) has released positive data regarding its Prime Editing technology therapy PM359, which was used to treat a patient with Chronic Granulomatous Disease (CGD) [2] Company Overview - Prime Medicine specializes in innovative gene editing technologies, particularly focusing on Prime Editing, which has shown promise in treating genetic disorders [2] Treatment Details - The therapy PM359 was administered to a patient suffering from CGD, and the results indicate a successful application of the technology [2]

Core Points - Prime Drink Group Corp. has changed its auditors from MNP LLP to Horizon Assurance LLP [1] - The Former Auditor resigned on June 25, 2025, and the Successor Auditor was appointed effective June 30, 2025 [1] - There were no reservations in the Former Auditor's audit reports for the relevant period [2] - The Company filed a Change of Auditor Notice on July 3, 2025, in compliance with National Instrument 51-102 [2] - Both auditors confirmed agreement with the statements in the respective Notices [2] Company Information - The appointment of the Successor Auditor will remain effective until the next Annual General Meeting of the Company [1] - There were no reportable events between the Former Auditor and the Company as defined in NI 51-102 [2]

Pipeline and Programs - Prime Medicine expects to file IND and/or CTA for Wilson's Disease program (PM577) in the first half of 2026 and announce initial clinical data in 2027[10] - Prime Medicine anticipates filing IND and/or CTA for AATD program in mid-2026 and expects initial clinical data in 2027[10] - Prime Medicine will share in vivo proof-of-concept data in CF and initiate IND-enabling studies[10] Technology and Safety - Prime Editing is designed to edit, correct, insert, and delete DNA sequences in any target tissue[12] - Prime Editing has a highly differentiated safety profile with no off-target activity detected in any lead program, including no detectable double-strand breakage, off-target edits, bystander edits, or large deletions/translocations[14, 15, 16, 17, 25] Partnerships and Financials - Prime Medicine entered into a strategic research collaboration and license agreement with Bristol Myers Squibb (BMS) to develop and commercialize multiple ex vivo T cell products in immunology and oncology, receiving $110 million upfront and potentially over $3.5 billion in milestones plus royalties[34, 85] - Prime Medicine entered into an agreement with the CF Foundation for up to $15 million to support the development of Prime Editors for Cystic Fibrosis[33, 77] - Prime Medicine held cash equivalents, investments, and restricted cash of $158.3 million as of March 31, 2025, providing a cash runway into the first half of 2026[98] Liver Programs - In Wilson's Disease, Prime Editors efficiently correct the two most prevalent disease-causing mutations, H1069Q and R778L, reducing liver copper by approximately 75%, decreasing urinary copper by about 80%, and increasing fecal copper by around 100% in vivo[52, 56] - In AATD, Prime Editor efficiently corrects the mutation resulting in M-AAT protein restoration in vivo, with the potential to correct mutated protein back to wild type without bystander or off-target edits[69, 71] - Prime Medicine achieved >70% hepatocyte editing using Prime Editors delivered with universal liver LNPs in humanized mice[37]

Core Viewpoint - Prime Drink Group Corp. is initiating a rights offering to raise a minimum of $3 million, aimed at recapitalizing the company and facilitating the acquisition of Triani Canada Inc. from receivership [1][2][4]. Group 1: Rights Offering Details - The company will offer a maximum of 353,409,888 rights to existing shareholders, with each right allowing the purchase of one share at a price of $0.0825 [1][3]. - The rights offering is expected to result in a total of 706,819,776 shares outstanding if all rights are exercised, with the new shares representing 50% of the total [3]. - The rights will expire on July 25, 2025, at 4:00 p.m. Eastern time, after which unexercised rights will be void [5]. Group 2: Use of Proceeds - Proceeds from the rights offering are intended for re-acquiring Triani and for general working capital, corporate purposes, and administrative expenses [10]. - The company aims to participate in the process of re-acquiring Triani, which is currently in receivership due to creditor actions [4]. Group 3: Shareholder Participation - The rights will only be offered to shareholders residing in Canada, and registered shareholders must submit their subscription forms to the rights agent by the expiry time [6][7]. - Directors and senior officers of the company are expected to exercise a portion of their rights, although the exact number cannot be determined at this time [10].